Recombinant human erythropoietin - Max Planck Institute

Drug Profile

Recombinant human erythropoietin - Max Planck Institute

Latest Information Update: 26 Jun 2015

Price : $50

At a glance

  • Originator Max Planck Institute of Experimental Medicine
  • Class Antianaemics; Recombinant erythropoietins; Recombinant fusion proteins
  • Mechanism of Action Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Multiple sclerosis; Schizophrenia

Most Recent Events

  • 21 Sep 2006 Phase-II clinical trials in Multiple sclerosis in Germany (unspecified route)
  • 21 Sep 2006 Phase-II clinical trials in Schizophrenia in Germany (IV)
  • 21 Sep 2006 Stem Cell Therapeutics has entered into an Option to Acquire agreement for the erythropoietin based therapies for the treatment of multiple sclerosis and schizophrenia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top